Investors
Welcome to our Investor Centre
Please click on the Profiles below to see more details on our other clients:
All of the information contained within this website has been compiled from sources believed to be reliable, but no warranty, expressed or implied, is given that the information is complete or accurate or that it is fit for a particular purpose. All such warranties are expressly disclaimed and excluded. Any opinions, recommendations and forecasts referred to are not those of Walbrook PR Limited but are expressly those of third parties, such as investment analysts and financial journalists. Such opinions, recommendations and forecasts may have been superseded and thus may not necessarily be the current opinions, recommendations and forecasts of the relevant analyst/broker. None of the content of this website should be construed as an offer to buy or sell, or a solicitation of an offer to buy or sell, the securities of any listed Company mentioned or featured herein as it is for information only. Any recommendations referred to by third parties do not necessarily imply the suitability of particular securities for individual situations. The value of securities and the income from them may fluctuate. It should be remembered that past performance is not necessarily a guide to future performance. You are strongly advised to seek guidance from a professional investment adviser before entering into any contract to buy or sell any security featured herein. By reading this disclaimer, and ticking the box below, you confirm that you accept and understand its content, and that you shall not hold Walbrook PR Limited, its directors and staff nor any of its subsidiaries or connected companies liable for any loss that you may sustain should you decide to buy or sell any of the mentioned securities.
Genedrive plc
Company Profile
Genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications.
The Company has assays on the market for the detection of MT-RNR1, HCV, certain military biological targets, a high throughput SARS-CoV-2 assay and a point of care test for Covid-19.
The company are currently developing a genetic test for CYP2C19 metaboliser status.
Latest Company Summary
Investor Access
The Company will be announcing its interim results for the six months ended 31 December 2023 on 28 March 2024.
The Company will provide a live presentation on Friday, 5 April 2024.
Investors can sign up to Investor Meet Company for free and add to meet genedrive plc: https://www.investormeetcompany.com/genedrive-plc/register-investorFriday 5 April 2024 at 10am
Event | Date |
Year End | 30 June |
Half Year End | 31 December |
Preliminary Results | November |
Interim Results* | March |
AGM* | May |
* Months based on previous announcements of this kind